hVIVO plc Directors' Dealings (2549B)
05 Outubro 2015 - 10:00AM
UK Regulatory
TIDMHVO
RNS Number : 2549B
hVIVO plc
05 October 2015
For immediate release 2.00pm: 5 October 2015
HVIVO PLC
("hVIVO" or the "Company")
Directors' Dealings
hVIVO plc (AIM: HVO), the pioneer of human challenge models of
disease, announces that application has been made to AIM for the
admission of 6,026 new ordinary shares of 5.0p each in the Company
(the "New Ordinary Shares").
The New Ordinary Shares have been allotted pursuant to the
purchase by Jaime Ellertson (Non-Executive Chairman) and Jim
Winschel (Non-Executive Director) of new ordinary shares, under the
terms of their letters of appointment as set out in the Company's
announcement of 4 November 2014 which stated that Mr Ellertson and
Mr Winschel had entered into binding commitments to purchase
$20,000 and GBP4,000 of new Retroscreen shares per quarter
respectively. The New Ordinary Shares represent their investments
for the quarter ended 30 September 2015. On 5 October 2015, Mr
Ellertson invested in an additional 4,616 ordinary shares and Mr
Winschel invested in an additional 1,410 ordinary shares.
Following admission of the 6,026 New Ordinary Shares to trading
on AIM, the total number of ordinary shares with voting rights in
issue will be 68,941,673 and this figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure and Transparency Rules.
Admission of the New Ordinary Shares ("Admission"), which will
rank pari passu in all respects with the Company's existing shares
in issue, is expected to occur on 9 October 2015. Following
Admission, Mr Ellertson and Mr Winschel will be interested in a
total of 25,165 and 26,413 ordinary shares of 5.0p in the Company
respectively, each representing less than 0.1% of the Company's
issued share capital.
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries +44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and Public
Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
hVIVO plc ("hVIVO") is a life sciences company pioneering a
technology platform of human disease models to accelerate drug
development and discovery in respiratory and infectious diseases.
Based in the UK, hVIVO has conducted over 40 clinical studies,
involving more than 2,000 volunteers for a range of leading
industry, governmental and academic clients.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSUGGBGUUPAGPA
(END) Dow Jones Newswires
October 05, 2015 09:00 ET (13:00 GMT)
Retroscreen (LSE:RVG)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Retroscreen (LSE:RVG)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024